Retrospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jul 27, 2022; 14(7): 670-684
Published online Jul 27, 2022. doi: 10.4240/wjgs.v14.i7.670
Impact of comorbid renal dysfunction in patients with hepatocellular carcinoma on long-term outcomes after curative resection
Yuzuru Sakamoto, Shingo Shimada, Toshiya Kamiyama, Ko Sugiyama, Yoh Asahi, Akihisa Nagatsu, Tatsuya Orimo, Tatsuhiko Kakisaka, Hirofumi Kamachi, Yoichi M Ito, Akinobu Taketomi
Yuzuru Sakamoto, Shingo Shimada, Toshiya Kamiyama, Ko Sugiyama, Yoh Asahi, Akihisa Nagatsu, Tatsuya Orimo, Tatsuhiko Kakisaka, Hirofumi Kamachi, Akinobu Taketomi, Department of Gastroenterological Surgery, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Hokkaido, Japan
Yoichi M Ito, Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo 060-8648, Hokkaido, Japan
Author contributions: Sakamoto Y, Shimada S, Kamiyama T contributed to the conception and design; Kamiyama T, Kamachi H, Taketomi A involved in the provision of study materials or patients; Sakamoto Y, Shimada S, Sugiyama K, Asahi Y, Nagatsu A, Orimo T, Kakisaka T contributed to the collection and assembly of data; Sakamoto Y, Shimada S, Kamiyama T, Ito YM involved in the data analysis and interpretation; all authors contributed to the manuscript writing; and all authors approved final manuscript.
Institutional review board statement: This study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and approved by the Institutional Review Board of Hokkaido University Hospital (No. 016-0354).
Informed consent statement: Voluntary written consent was obtained from all patients.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: We cannot share the data collected for our study with others because of the confidentiality rules of our hospital.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shingo Shimada, MD, PhD, Surgeon, Department of Gastroenterological Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Hokkaido, Japan. shingoshimada1979@true.ocn.ne.jp
Received: January 30, 2022
Peer-review started: January 30, 2022
First decision: March 12, 2022
Revised: March 28, 2022
Accepted: July 11, 2022
Article in press: July 11, 2022
Published online: July 27, 2022
Processing time: 178 Days and 5.2 Hours
Core Tip

Core Tip: This retrospective study revealed that comorbid renal dysfunction (RD) had a negligible impact on the prognosis of hepatocellular carcinoma patients who underwent curative hepatectomy with appropriate perioperative management, and close attention to severe chronic kidney disease is necessary to prevent postoperative bleeding and surgical site infection. Of particular interest is the finding that regardless of the degree of comorbid RD, the overall survival rate and recurrence-free survival rate were comparable, even when using a propensity model to exclude the influence of patient characteristics, liver function, and other causes of death. Moreover, no RD patient, even severe RD patients, received maintenance hemodialysis after hepatectomy.